Thermo Fisher Scientific Inc. of Waltham, Mass., has acquired Intrinsic Bioprobes Inc. of Tempe, Ariz., to enhance its work flow for biomarker research and diagnostics. Intrinsic Bioprobes’ portfolio, including its mass spectrometric immunoassay, will enable Thermo Fisher to offer its life sciences research and clinical diagnostics customers an enhanced solution for quantitative protein biomarker detection. Intrinsic Bioprobes manufactures immuno-enrichment sample-preparation tools used in quantitative mass spectrometry. Thermo Fisher also has completed the acquisition of Phadia of Uppsala, Sweden, a provider of blood tests for clinical diagnosis and monitoring of allergies and autoimmune diseases, adding it to its Specialty Diagnostics business.